Comparative Pharmacology
Head-to-head clinical analysis: ALTRENO versus TRETINOIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALTRENO versus TRETINOIN.
ALTRENO vs TRETINOIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; believed to involve reduction of hepatic glucose production and improvement of insulin sensitivity via AMPK activation.
Retinoic acid receptor agonist; binds to RAR and RXR nuclear receptors, modulating gene transcription involved in cell differentiation, proliferation, and apoptosis.
ALTRENO is not a recognized drug. No data available.
Acute promyelocytic leukemia (APL): 45 mg/m2/day orally divided twice daily, as induction therapy.
None Documented
None Documented
Terminal elimination half-life is 20-30 hours; steady state reached in 5-7 days.
Clinical Note
moderateTretinoin + Digoxin
"Tretinoin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateAlitretinoin + Digoxin
"Alitretinoin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateTretinoin + Digitoxin
"Tretinoin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateAlitretinoin + Digitoxin
"Alitretinoin may decrease the cardiotoxic activities of Digitoxin."
Terminal elimination half-life is 0.5-2 hours for the parent drug, but may be prolonged to 10-12 hours after multiple dosing due to reduced clearance; clinical context: t1/2 is short, requiring frequent or continuous dosing to maintain therapeutic levels.
Primarily renal (70-80% as unchanged drug), with 10-15% biliary/fecal elimination.
Primarily fecal (approx. 60%) via biliary excretion as metabolites; renal excretion accounts for <15% of a dose as unchanged drug and metabolites.
Category C
Category D/X
Retinoid
Retinoid